Lee's Pharmaceutical Holdings (FRA:L1PA) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:L1PA Lee's Pharmaceutical Holdings Ltd FRA:L1PA
74 GF Score
Price €0.12
GF Value €0.17
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lee's Pharmaceutical Holdings  (FRA:L1PA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lee's Pharmaceutical Holdings Cyclically Adjusted PS Ratio Related Terms


Lee's Pharmaceutical Holdings Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Lee's Pharmaceutical Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lee's Pharmaceutical Holdings Cyclically Adjusted PS Ratio Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 0.86 0.74 0.70 0.64

Lee's Pharmaceutical Holdings Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.69 0.61 0.64 0.42

FRA:L1PA vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Cyclically Adjusted PS Ratio falls into.


FRA:L1PA
74GF Score
Lee's Pharmaceutical Holdings Ltd FRA:L1PA
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lee's Pharmaceutical Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lee's Pharmaceutical Holdings's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Lee's Pharmaceutical Holdings's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=0.277/120.7036*120.7036
=0.277

Current CPI (Dec25) = 120.7036.

Lee's Pharmaceutical Holdings Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.183 103.225 0.214
201712 0.194 104.984 0.223
201812 0.207 107.622 0.232
201912 0.235 110.700 0.256
202012 0.234 109.711 0.257
202112 0.234 112.349 0.251
202212 0.254 114.548 0.268
202312 0.211 117.296 0.217
202412 0.282 118.945 0.286
202512 0.277 120.704 0.277

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lee's Pharmaceutical Holdings (FRA:L1PA) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of €0.12 is trading 27.1% below its estimated GF Value™ of €0.17.

Key valuation signals for FRA:L1PA:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.17 vs. price of €0.12 (27.1% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:L1PA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lee's Pharmaceutical Holdings Business Description

Other Exchanges 00950:Hong Kong
Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score

Get the complete analysis for FRA:L1PA

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.17
GF Value